Drugs / SAR444200
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05450562 | Sep 2022 → Dec 2025 | neoplasm | Sanofi | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR444200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05450562 ↗ |
| Route | Intravenous | “Route of administration: intravenous (IV) infusion” NCT05450562 ↗ |